The future of cancer vaccines for non-small-cell lung cancer: Ongoing trials

Clinical Lung Cancer

Volumn 9, Issue SUPPL. 1, 2008, Pages

  Choudhury, Aniruddha ^a   Palma, Marzia ^a   Mellstedt, Håkan ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

BLP25; Cell derived vaccines; Gene modified vaccines; GM CSF vaccine

Indexed keywords

CANCER VACCINE; EPIDERMAL GROWTH FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; MONOCLONAL ANTIBODY; SRL 172; UNCLASSIFIED DRUG;

CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG TOLERABILITY; FOLLOW UP; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; LUNG NON SMALL CELL CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SAFETY; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 40449089463     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2008.s.006     Document Type: Article

References (25)

1. DM Parkin F Bray J Ferlay Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108
2. J Dancey FA Shepherd RJ Gralla Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial Lung Cancer 43 2004 183 194
3. JL Pujol S Paul N Chouaki Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis J Thorac Oncol 2 2007 397 401
4. R Feld SS Sridhar FA Shepherd Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review J Thorac Oncol 1 2006 367 376
5. NP Restifo SA Rosenberg Use of standard criteria for assessment of cancer vaccines Lancet Oncol 6 2005 3 4
6. AB Miller B Hoogstraten M Staquet Reporting results of cancer treatment Cancer 47 1981 207 214
7. P Therasse SG Arbuck EA Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
8. B Chan W Lee CX Hu Adoptive cellular immunotherapy for non-small cell lung cancer: a pilot study Cytotherapy 5 2003 46 54
9. EA Hirschowitz T Foody R Kryscio Autologous dendritic cell vaccines for non-small-cell lung cancer J Clin Oncol 22 2004 2808 2815
10. J Nemunaitis RO Dillman PO Schwarzenberger Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer J Clin Oncol 24 2006 4721 4730
11. LE Raez PA Cassileth JJ Schlesselman Induction of CD8 T-cell-Ifn-gamma response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma Cancer Gene Ther 10 2003 850 858
12. LE Raez PA Cassileth JJ Schlesselman Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced nonsmall-cell lung cancer J Clin Oncol 22 2004 2800 2807
13. R Salgia T Lynch A Skarin Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma J Clin Oncol 21 2003 624 630
14. J Nemunaitis D Sterman D Jablons Granulocyte-macrophage colonystimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer J Natl Cancer Inst 96 2004 326 331
15. J Nemunaitis T Jahan H Ross Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer Cancer Gene Ther 13 2006 555 562
16. M Palmer J Parker S Modi Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-smallcell lung cancer Clin Lung Cancer 3 2001 49 57 discussion 58.
17. G Gonzalez T Crombet F Torres Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy Ann Oncol 14 2003 461 466
18. D Atanackovic NK Altorki E Stockert Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients J Immunol 172 2004 3289 3296
19. J Vansteenkiste M Zielinski J Dahabre Multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of recombinant MAGE-A3 vaccine as adjuvant therapy in stage IB/II MAGE-A3-positive, completely resected, non small cell lung cancer (NSCLC) J Clin Oncol 24 18 suppl 2006 368s (Abstract 7019).
20. ME O'Brien A Saini IE Smith A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma Br J Cancer 83 2000 853 857
21. ME O'Brien H Anderson E Kaukel SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results Ann Oncol 15 2004 906 914
22. C Butts N Murray A Maksymiuk Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer J Clin Oncol 23 2005 6674 6681
23. EA Hirschowitz T Foody GE Hidalgo Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells Lung Cancer 57 2007 365 372
24. RA Graham JM Burchell J Taylor-Papadimitriou The polymorphic epithelial mucin: potential as an immunogen for a cancer vaccine Cancer Immunol Immunother 42 1996 71 80
25. ClinicalTrials.gov Web site. Available at: http://www.clinicaltrials.gov Accessed: May 5, 2007.